Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04521699 · ClinicalTrials.gov registry record · NA
Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.
A NA study of Myocardial Infarction, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04521699: Recruiting NA study of Myocardial Infarction, sponsored by Mayo Clinic.
NCT04521699 is a NA study of Myocardial Infarction that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 100 participants, below the 4,680-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04521699, a NA study of Myocardial Infarction, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to determine if there are significant differences with respect to baseline between those randomized to CGo and standard-of-care versus standard-of-care alone after completing 12-weeks of therapy in terms of peripheral endothelial function measured by EndoPAT.
Primary Outcome
Measurements made at baseline will be significantly different between those randomized to CalmioGo + standard of care to those receiving only standard of care treatment
Conditions Studied
Interventions
- DEVICE CalmioGO Stress management device
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT04521699 shows while recruiting
NCT04521699 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 4,680-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 1 intervention - of which CalmioGO Stress management device is the first listed.
NCT04521699 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04521699 about?
NCT04521699 is a clinical study titled "Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.". The primary purpose of this study is to determine if there are significant differences with respect to baseline between those randomized to CGo and standard-of-care versus standard-of-care alone after completing 12-weeks of therapy in terms of peripheral endothelial function measured by EndoPAT.
What is the current status of trial NCT04521699?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-01-13. Estimated completion is 2026-12.
What conditions does trial NCT04521699 study?
This clinical trial studies the following conditions: Myocardial Infarction.
What interventions are being tested in trial NCT04521699?
The interventions under investigation include: CalmioGO Stress management device (DEVICE).
Who is sponsoring clinical trial NCT04521699?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04521699 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04521699's enrollment target sits among peer trials
100 53rd of 64 higher than 12 of 64 other Myocardial Infarction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myocardial Infarction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
Women's Heart Attack Research Program: Stress Ancillary Study
RECRUITING · NA
-
Cardiac Radioablation for VT
RECRUITING · NA
-
Reducing Blood Pressure in Patients With High Cardiovascular Risk
RECRUITING · NA
-
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia
RECRUITING · NA
-
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI